Oculis Holding AG - Ordinary shares (id:6584 OCS)
16.82 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 11:12:09 AM)
Exchange open, closes in 4 hours 47 minutes
-2.58 USD (-2.58%)
-3.84 USD (-3.84%)
14.38 USD (14.38%)
41.62 USD (41.62%)
55.93 USD (55.93%)
73.27 USD (73.27%)
About Oculis Holding AG - Ordinary shares
Market Capitalization 686.22M
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
| Headquarters (address) |
Bahnhofstrasse 7 Zug 6300 Switzerland |
| Phone | 41 41 711 9325 |
| Website | https://oculis.com |
| Employees | 36 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | OCS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 10.10 - 18.00 |
| Market Capitalization | 686.22M |
| P/E trailing | 63.63 |
| P/E forward | -7.30 |
| Price/Sale | 790.58 |
| Price/Book | 7.21 |
| Beta | 5.00 |
| EPS | -1.88 |
| EPS Switzerland (ID:153, base:188) | 28.46 |